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Deprivation and prognosis in patients
with pulmonary arterial hypertension:
missing the effect of deprivation on a
rare disease?
To the Editor:
In this journal, PELLINO et al. [1] presented a survival analysis to assess how deprivation affects prognosis
in patients with pulmonary arterial hypertension (PAH). Their conclusions were that social deprivation is
not a significant referral barrier or prognostic factor for idiopathic (I)PAH or heritable (H)PAH in
Scotland. This may appear surprising, given the wider context of literature describing outcomes stratified
by social deprivation. The authors were thorough on using both the address at time of diagnosis and at
time of censoring to assign deprivation scores and compare the two, finding no significant differences
between the two approaches. They also compared deprivation assigned to PAH cases to expected
deprivation based on Scottish citizenry as a whole, and found that PAH patients are more socially
deprived than expected. Finally, they used the same survival univariate analysis adjusting for age and sex
to assess how several clinical variables are associated with prognosis.
The ongoing National Cohort Study of Idiopathic and Heritable PAH collects data from all of the UK and
offers an opportunity to test the relationship between deprivation and outcomes in PAH in a second
population that is geographically distinct but in many other ways highly analogous to that studied by
PELLINO et al. [1]. The study collects data from a contemporaneous cohort in all of the specialist PAH
centres in the UK. Therefore, we were able to assess mortality in relation to deprivation in 270 PAH
patients living in England and Wales, residing in the same addresses since diagnosis. Our patients were
recruited in the UK PAH cohort from 1 January, 2014 and followed-up until 28 February, 2019. 36 (13%)
participants died and five (2%) were transplanted, resulting in 1-, 3- and 5-year transplant-free survival
estimates of 96%, 86% and 73% for incident patients (n=146) and 100%, 100% and 89% for prevalent
patients (n=124), respectively. PELLINO et al. [1] captured deprivation using the Scottish Index of Multiple
Deprivation (IMD), which is a composite index comprising of sub-indices (e.g. income, education,
employment, health, access to services, crime). In the UK, IMD is not comparable between England,
Scotland and Wales, so for our UK cohort we accessed an adjusted IMD index for use across the UK [2],
which consists of the three main domains of IMD: income, employment and educational deprivation. In
addition to the area level deprivation captured via the UK-IMD, the primary survival model was adjusted
for age at diagnosis and sex, to be in line with the adjustment used by PELLINO et al. [1], fitting Cox
proportional hazards regression models. Cox proportional hazards regression models and survival curves
were fitted allowing for left truncation arising from the interval between diagnosis of prevalent cases and
enrolment. Prevalent patients were only included in the risk set from the time of study entry and were
excluded if they entered the study >10 years after diagnosis. We stratified the analysis by centre, due to the
multicentre design of our study. In the extended model, we further adjusted for smoking, prevalent/
incident status and risk profiles (low/intermediate/high) at the time of diagnosis, calculated using the
abbreviated 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) risk
stratification strategy [3]. According to data availability, the risk score groups were estimated using the
World Health Organization functional class, right atrial pressure, cardiac index and mixed venous oxygen
saturation, having significant difference (p=0.02) on survival (figure 1), as expected.
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No association was found between deprivation and mortality for PAH patients in England and Wales.
The association found between risk stratification at baseline and deprivation suggests that the issue of
deprivation and outcomes in PAH may be more nuanced. https://bit.ly/2y8WgqB
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The study participants are more likely to be women (68%) with mean±SD age at diagnosis 51±16 years.
The pulmonary haemodynamic characteristics of the study participants were: 1) right atrial pressure
9±5 mmHg, 2) mean pulmonary arterial pressure, 53±14 mmHg, 3) cardiac index 2±0.6 L·min−1·m−2,
4) cardiac output 4±1.2 L·min−1, 5) pulmonary vascular resistance 12±5 WU and 6) mixed venous oxygen
saturation, 64±8%. We found no association between mortality and classes of area deprivation, for both
the primary and adjusted model. As an example, adjusted hazard ratio (HR) was 0.63 (95% CI 0.18–2.16)
(p=0.458) for most deprived (quintile 5) areas compared to least deprived (quintile 1) areas. To examine
this further, we investigated area deprivation as predictor of risk profiles, fitting multinomial regression
models. We found an association between risk profiles and area deprivation, while adjusting for the same
variables as above. Living within the more deprived areas (quintiles 5, 4 and 3) was associated with higher
PAH risk score at baseline, compared to the least deprived areas (quintile 1), therefore increasing the
likelihood of being diagnosed within the ESC/ERS high-risk clinical prediction category. Testing for the
overall effect of deprivation to risk profiles, we found a statistically significant predictor effect (p=0.034,
Wald-test). The relative risk ratio changing from least (quintile 1) to most (quintile 5) deprived area is
15.01 (95% CI 1.96–114.96) (p=0.009), for being classed as high risk profile versus low risk profile. This
was 14.59 (95% CI 2.22–95.9) (p=0.005) and 9.75 (95% CI 1.42–67.06) (p=0.021) for quintiles 4 and 3,
respectively. In other words, we found that the expected risk for being in high-risk class is higher for
subjects who live in the most deprived areas. The baseline risk class was also found to be a predictor of
mortality in this survival analysis (adjusted HR 6.71, 95% CI 1.22–36.87) (p=0.028), in line with the
literature [3–5].
The notion that deprivation is associated with increased mortality and morbidity for the most deprived
compared with the most affluent, is confirmed by many studies and, therefore, has been enshrined in
health studies, theories and policies [6–9]. The main aspects of deprivation are income, employment and
education that can be collected at area-level and individual level or, preferably, both. The choice for using
a composite index or its subdomains, or individual-level deprivation, is driven by the research question
and availability of deprivation indicators. Studies have faced numerous challenges in terms of using a
composite area-level deprivation index. The data required are based on coverage of routinely collected
data, which can vary between countries, using also a weighting score that depends on the priorities set by
each country, making these indices not comparable. Usually, though, the highest weights are given to
income, employment and educational deprivation and, therefore, it is possible the composite index is
similar to indices that are based on any of these traditional deprivation markers. Still, we recommend not
to assume that any differences would have no impact on the results, especially when using small datasets
as the models can be too sensitive.
Even when such an index is used for the intended geographical area it was created for, the geographical
distributions of sub-indices may have opposing directions, introducing error on the overall measure of
deprivation. For instance, a high deprivation score should reflect both areas of low income and difficulty
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FIGURE 1 Transplant-free survival in relation to risk profile (Kaplan–Meier estimates), at the time of diagnosis
(n=270).
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in accessing healthcare, with the latter often being measured as distance to primary healthcare centre.
Patients who live near city centres, which tend to have higher income deprivation, may not have a long
distance to access a primary care centre, while the opposite holds for wealthier populations that may live
outside the city centre. Thus, the estimated composite deprivation can be compromised. Even the
traditional indicators of income and education deprivation may vary substantially across areas [10]. Any
differences can be understood by mapping the individual domains, which is important when considering
how such data is used in analyses.
Composite IMD indices, such as the Scottish IMD used by PELLINO et al. [1], have a health subdomain
calculated based on standardised mortality ratio among other variables, so PAH mortality may be captured
in some degree by this sub-domain. Therefore, ideally, the health sub-domain should not be included
when deprivation is examined in relation to mortality. Finally, we would argue that even when prognosis is
not associated with deprivation, this cannot directly lead to the interpretation that prognosis is not affected
by access to care and referrals. Deprivation is linked to several parameters that affect health (i.e. diet, air
quality) other than just equity on access to health services.
A notable feature of the UK National Health Service specialised commissioning structure for PAH is the
equity of access to all licensed treatments to all patients, once they have been referred to the centres. A
possible interpretation of our results and those reported by PELLINO et al. [1] is therefore that deprivation
acts as a barrier to referral but once in the specialised system, the equity of treatment availability
diminishes the subsequent effect on mortality. We feel it cannot be ignored that, unlike previous work that
showed a significant effect of deprivation on mortality [11], both UK studies of similar sample sizes have
failed to demonstrate an association with mortality and in health systems with more equal access to
licensed treatment.
There are some limitations to this work. It is common for rare disease projects to analyse hundreds of
cases, compared to thousands or millions in common diseases, for the same or similar research questions
[12, 13], leading to the need to adopt refined datasets and analytical methods. The introduction of
measurement error when using a deprivation index is likely to affect small datasets disproportionately and
needs to be used with caution when conducting sensitivity analysis. Lastly, we are unable to quantify the
effect of patients potentially not surviving to first admission to a tertiary PH care centre, and this drop out
is theoretically more significant, specifically because of the association we find with baseline risk
stratification.
Overall, the study by PELLINO et al. [1] is an important piece in the PAH aetiology puzzle, and the results
of our study are in line with their lack of association between mortality and social deprivation; although
we would caution that both studies are of modest size. At the same time, PELLINO et al. [1] found that PAH
patients are more socially deprived than expected, based on Scottish citizenry as a whole. This alludes that
deprivation status may have an association with PAH rather than it being a random finding. Our study
adds further to the literature by demonstrating that higher area deprivation is associated with a worse risk
profile at baseline, which in turn is a predictor of worse survival rates, suggesting that the issue of social
deprivation and outcomes in PAH may be more nuanced. Examining both primary healthcare and
hospital data in PAH could provide evidence on whether in deprived areas delays on PAH diagnosis are
associated with the patient taking longer to seek help and the time required for tests related to the
diagnosis, compared to least deprived areas.
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